Becton, Dickinson and Company $BDX Holdings Lifted by Palouse Capital Management Inc.

Palouse Capital Management Inc. increased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 34.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 13,283 shares of the medical instruments supplier’s stock after acquiring an additional 3,393 shares during the period. Palouse Capital Management Inc.’s holdings in Becton, Dickinson and Company were worth $2,010,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Brighton Jones LLC boosted its holdings in Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after buying an additional 877 shares in the last quarter. Empowered Funds LLC grew its position in Becton, Dickinson and Company by 20.4% in the first quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock worth $1,827,000 after buying an additional 1,354 shares during the last quarter. United Bank increased its holdings in shares of Becton, Dickinson and Company by 23.9% in the second quarter. United Bank now owns 5,149 shares of the medical instruments supplier’s stock valued at $887,000 after buying an additional 993 shares in the last quarter. Marshall Wace LLP lifted its position in shares of Becton, Dickinson and Company by 365.1% during the 2nd quarter. Marshall Wace LLP now owns 31,876 shares of the medical instruments supplier’s stock valued at $5,491,000 after acquiring an additional 25,022 shares during the last quarter. Finally, NewEdge Advisors LLC lifted its position in shares of Becton, Dickinson and Company by 34.7% during the 2nd quarter. NewEdge Advisors LLC now owns 23,501 shares of the medical instruments supplier’s stock valued at $4,048,000 after acquiring an additional 6,058 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Price Performance

BDX opened at $177.40 on Friday. The firm has a market capitalization of $48.88 billion, a P/E ratio of 44.91, a PEG ratio of 12.16 and a beta of 0.19. The stock has a fifty day moving average of $153.78 and a 200-day moving average of $162.41. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating the consensus estimate of $3.14 by $0.09. The firm had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.Becton, Dickinson and Company’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the previous year, the firm earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities analysts forecast that Becton, Dickinson and Company will post 12.53 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be issued a $1.05 dividend. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.4%. Becton, Dickinson and Company’s dividend payout ratio is currently 106.33%.

Insider Buying and Selling

In related news, EVP Michael David Garrison sold 1,100 shares of the business’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the transaction, the executive vice president directly owned 13,172 shares of the company’s stock, valued at approximately $1,918,633.52. The trade was a 7.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. The trade was a 2.45% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 5,189 shares of company stock valued at $765,661 over the last three months. 0.40% of the stock is owned by insiders.

Trending Headlines about Becton, Dickinson and Company

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: BD reported fiscal Q3 revenue of approximately $5.0 billion, up 5.4% year over year and ahead of the $4.89 billion consensus estimate. Broad growth across its Medical Essentials and Interventional segments helped offset weaker areas. BD Reports Third Quarter Fiscal 2026 Financial Results
• Positive Sentiment: Adjusted diluted EPS was $3.23, beating analysts’ $3.14 estimate by $0.09. The company raised its fiscal 2026 adjusted EPS guidance to $12.62-$12.72, above the roughly $12.56 consensus, and expects revenue growth toward the high end of its previous range. Becton Dickinson Signals Strong Growth Momentum By Raising Profit Outlook
• Positive Sentiment: BD reported solid cash-flow improvement: year-to-date cash from continuing operations rose 33.3% to $2.1 billion, while free cash flow increased 44.6% to $1.7 billion. This supports balance-sheet flexibility and the company’s earnings-quality narrative. BD Reports Third Quarter Fiscal 2026 Financial Results

Analyst Upgrades and Downgrades

BDX has been the topic of a number of recent research reports. Piper Sandler decreased their target price on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a report on Friday, April 17th. Wells Fargo & Company increased their price target on Becton, Dickinson and Company from $157.00 to $161.00 and gave the company an “equal weight” rating in a research report on Friday, May 8th. Zacks Research raised Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research note on Friday, April 10th. Barclays upped their price objective on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Finally, TD Cowen raised their target price on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a report on Wednesday. Eight investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $183.53.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.